Borealis’ Bormed™ LE6609-PH puts high temperature sterilisation in the spotlight at Pharmapack 2010

22.01.2010

Borealis, a leading provider of chemical and innovative plastics solutions, will feature Bormed™ LE6609-PH for pharmaceutical packaging for intravenous solutions and medicines at Pharmapack 2010 Stand D26 from February 1-2, 2010 in Paris.

The latest addition to its Bormed range of dedicated polyolefins for healthcare applications, Bormed LE6609-PH makes its first appearance at the annual Pharmapack event alongside the comprehensive film and moulded packaging innovations designed to meet the superior technical performance and challenging service requirements of the healthcare market.

Bormed is Borealis’ special healthcare product line offering 4 pillars: dedicated materials, additional support, security of supply and innovation. Bormed LE6609-PH was introduced to the market in mid- 2009, following the successful launch of LE6607-PH for soft and flexible bottles at Pharmapack 2009, to meet demands for greater security for sterilised products, reductions in material use and more efficient manufacturing.

This transparent, Blow Fill and Seal (BFS) low density polyethylene offers a high density level and therefore a high melting point. The resulting high steam sterilisation temperature allows converters to reduce autoclave residence time by up to 1.5 hours, speeding up their production cycle, lowering energy use and improving efficiency.

In addition, Bormed LE6609-PH’s high density and optimised molecular weight distribution (MWD) offers the potential for material and weight reduction of up to 5-7%. Converters and brand owners can make more products of a lighter weight using the same material volume, while the resulting energy savings benefit both manufacturing costs and the environment.

With its Bormed family of dedicated polyolefins for the healthcare industry Borealis ensures a consistent, committed approach to material development for medical devices and pharmaceutical and diagnostic products. The polyethylene and polypropylene grades offer the security of supply, regulatory compliance, long-term traceability and reliability required by this highly-demanding, specialised sector.

Borealis’ EUR 50 million expansion of its Innovation Headquarters in Linz, Austria further reinforces its commitment to the industry. The latest plastics processing equipment, high-tech laboratories and the expertise of dedicated, international specialists are available at one single site, allowing faster and more customised product development tailored to the needs of the healthcare market.

“Patient safety is paramount to the healthcare industry and as a result product manufacturers require 100% confidence in materials, their regulatory compliance, and in the long-term support and technical capabilities of their suppliers,” comments Martyna Matelska-Jucha, Marketing Manager business unit Moulding. “Borealis’ Bormed materials and approach to R&D are focused on meeting these criteria. Using the latest development facilities at our Innovation Headquarters, dedicated production lines, global supply network and on-going customer support we are able to give the industry the peace of mind and performance capabilities it needs to bring safe, cutting-edge innovations to the market.”

Borealis’ Bormed materials are European Pharmacopeia (EP) and US Pharmacopeia compliant and are Drug Master File registered. In addition, most of the Bormed grades comply with biocompatibility standards as specified in ISO 10993.

For further information please contact:

Kerstin Meckler
Head of Communications, Borealis
Vienna, Austria
+43 1 22 400 389
kerstin.meckler@borealisgroup.com

Borealis is a leading provider of chemical and innovative plastics solutions that create value for society. With sales of EUR 6.6 billion in 2008, customers in over 120 countries, and 5,400 employees worldwide, Borealis is owned 64% by the International Petroleum Investment Company (IPIC) of Abu Dhabi and 36% by OMV, the leading energy group in the European growth belt. Borealis is headquartered in Vienna, Austria, and has production locations, innovation centers and customer service centers across Europe and the Americas. Through Borouge, a joint venture between Borealis and the Abu Dhabi National Oil Company (ADNOC), one of the world's major oil companies, the company's footprint reaches out to the Middle East, Asia Pacific, the Indian sub-continent and Africa. Established in 1998, Borouge employs approximately 1,400 people, has customers in more than 50 countries and its headquarters are in Abu Dhabi in the UAE and Singapore.

Building on the unique Borstar® technology and their experience in polyolefins for more than 50 years, Borealis and Borouge provide innovative, value creating plastics solutions for the infrastructure (pipe systems and power and communication cables), automotive and advanced packaging markets. In addition, Borealis offers a wide range of base chemicals from melamine and plant nutrients to phenol and acetone.

Today Borealis and Borouge manufacture 4.4 million tonnes of polyolefins (polyethylene and polypropylene) per year. Borouge is currently tripling its polyolefins manufacturing capacity to 2 million tonnes per year (t/y) by mid-2010 and an additional 2.5 million t/y is scheduled for 2013. The companies continue to invest to ensure that their customers throughout the value chain, across the globe, can always rely on product quality, consistency and security of supply.

Borouge and Borealis are committed to the principles of Responsible Care® and proactively contribute to addressing the world's water and sanitation challenges through their Water for the World™ initiative.

Upcoming event

Pharmapack 2012

Also Know More About

Sharing our views on plastics.

Downloads & Support